Gilead data show states with highest use of Truvada for PrEP had declines in HIV

Gilead Sciences announced results of a retrospective nationwide analysis of the impact of Truvada for pre-exposure prophylaxis, or PrEP, use across all 50 U.S. states and the District of Columbia. Conducted in collaboration with researchers at Emory University Rollins School of Public Health and the Centers for Disease Control and Prevention, these data demonstrate that use of once-daily oral Truvada for PrEP has had an independent and significant impact on the number of new HIV infections diagnosed in the United States from 2012 to 2016. The data were presented at the 22nd International AIDS Conference in Amsterdam. In the analysis, states with the highest utilization of Truvada for PrEP during this five year period had significant declines in the average number of HIV diagnoses, while there was an average increase for the states with the lowest use. The impact of Truvada for PrEP use occurred even after controlling for the effect of antiretroviral therapy use in those living with HIV, known as treatment as prevention, in a subset of 38 states and Washington, D.C., where virologic suppression data was available. Across all 50 states and Washington, D.C., Truvada for PrEP use prevalence increased from 7.0 to 68.5 per 1,000 people at highest risk of HIV acquisition during the five-year period, and the rate of new HIV diagnoses decreased significantly from 15.7 to 14.5 per 100,000 people among the general population.
https://bit.ly/2Odo0Os